Research Analysts Set Expectations for TVTX Q2 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Equities researchers at HC Wainwright dropped their Q2 2025 EPS estimates for Travere Therapeutics in a research note issued on Tuesday, July 1st. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($0.54) per share for the quarter, down from their previous estimate of ($0.38). HC Wainwright currently has a "Buy" rating and a $30.00 target price on the stock. The consensus estimate for Travere Therapeutics' current full-year earnings is ($1.40) per share. HC Wainwright also issued estimates for Travere Therapeutics' Q3 2025 earnings at ($0.62) EPS, Q4 2025 earnings at ($0.62) EPS, FY2025 earnings at ($2.30) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at ($0.17) EPS, FY2028 earnings at $0.13 EPS and FY2029 earnings at $0.47 EPS.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.08. The firm had revenue of $81.73 million during the quarter, compared to analyst estimates of $77.44 million. Travere Therapeutics had a negative net margin of 82.88% and a negative return on equity of 1,179.73%. The business's revenue for the quarter was up 83.3% on a year-over-year basis. During the same period in the previous year, the business posted ($1.76) earnings per share.

A number of other equities analysts also recently issued reports on TVTX. Bank of America raised their price target on Travere Therapeutics from $29.00 to $31.00 and gave the stock a "buy" rating in a research note on Tuesday, April 1st. Canaccord Genuity Group increased their target price on Travere Therapeutics from $45.00 to $47.00 and gave the company a "buy" rating in a report on Thursday, April 10th. Citigroup cut their price target on Travere Therapeutics from $35.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, June 11th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Travere Therapeutics in a research report on Wednesday, April 23rd. Finally, Guggenheim reissued a "buy" rating and issued a $47.00 price objective on shares of Travere Therapeutics in a report on Monday, April 14th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $32.14.

Travere Therapeutics Stock Performance

TVTX stock traded up $0.16 on Thursday, hitting $15.00. The company had a trading volume of 663,493 shares, compared to its average volume of 1,621,333. The company has a current ratio of 2.05, a quick ratio of 2.03 and a debt-to-equity ratio of 9.46. Travere Therapeutics has a 12-month low of $7.93 and a 12-month high of $25.29. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -5.34 and a beta of 0.72. The stock's 50-day simple moving average is $16.72 and its 200 day simple moving average is $18.14.

Insider Transactions at Travere Therapeutics

In other Travere Therapeutics news, CEO Eric M. Dube sold 18,924 shares of the firm's stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $21.05, for a total transaction of $398,350.20. Following the sale, the chief executive officer directly owned 419,173 shares of the company's stock, valued at $8,823,591.65. This trade represents a 4.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Christopher R. Cline sold 1,784 shares of the business's stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $21.05, for a total value of $37,553.20. Following the completion of the transaction, the chief financial officer owned 93,126 shares in the company, valued at $1,960,302.30. The trade was a 1.88% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 23,342 shares of company stock valued at $485,753 over the last three months. Corporate insiders own 4.06% of the company's stock.

Institutional Trading of Travere Therapeutics

Several institutional investors have recently made changes to their positions in TVTX. Bank of New York Mellon Corp boosted its stake in Travere Therapeutics by 3.6% in the 4th quarter. Bank of New York Mellon Corp now owns 216,863 shares of the company's stock worth $3,778,000 after purchasing an additional 7,513 shares during the period. US Bancorp DE lifted its holdings in shares of Travere Therapeutics by 323.4% in the fourth quarter. US Bancorp DE now owns 31,795 shares of the company's stock worth $554,000 after buying an additional 24,286 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Travere Therapeutics by 16.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 661,603 shares of the company's stock worth $11,525,000 after acquiring an additional 94,194 shares during the last quarter. Victory Capital Management Inc. purchased a new position in Travere Therapeutics during the fourth quarter valued at $182,000. Finally, Aigen Investment Management LP grew its stake in Travere Therapeutics by 56.6% during the fourth quarter. Aigen Investment Management LP now owns 19,072 shares of the company's stock valued at $332,000 after acquiring an additional 6,892 shares in the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.